The potential role of glucagon-like peptide 1 in diabetes

Current Opinion in Investigational Drugs

Volumn 5, Issue 4, 2004, Pages 402-410

  Meier, Juris J ^a   Nauck, Michael A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DIABETESZENTRUM BAD LAUTERBERG   (Germany)

Author keywords

DPP IV inhibitors; GLP 1; GLP 1 analogs; Glucagon like peptide 1; Incretin effect; Type 2 diabetes

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INSULIN; PEPTIDE FRAGMENT; PROTEIN PRECURSOR;

ANIMAL; BLOOD; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INSULIN; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 3042617876     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Elrick H, Stimmler L, Hlad CJ Jr, Arai Y: Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab (1964) 24:1076-1082.
2. Creutzfeldt W: The incretin concept today. Diabetologia (1979) 16(2):75-85.
3. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W: Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab (1986) 63(2):492-498.
4. Buffa R, Polak JM, Pearse AGE, Solcia E, Grimelius L, Capella C: Identification of the intestinal cell storing gastric inhibitory peptide. Histochemistry (1975) 43(3):249-255.
5. Bell GI, Santerre RF, Mullenbach GT: Hamster preproglucagon gene contains the sequence of glucagon and two related peptides. Nature (1983) 302(5910):716-718.
6. Ørskov C, Holst JJ, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV: Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology (1986) 119(4):1467-1475.
7. Ørskov C, Holst JJ, Nielsen OV: Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology (1988) 123(4):2009-2013.
8. Nauck M, Stöckmann F, Ebert R, Creutzfledt W: Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia (1986) 29(1):46-52.
9. Nauck MA, Bartels E, Ørskov C, Ebert R, Creutzfeldt W: Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab (1993) 76(4):912-917.
10. Amland PF, Jorde R, Aanderud S, Burhol PG, Giercksky K-E: Effects of intravenously infused porcine GIP on serum insulin, plasma C-peptide, and pancreatic polypeptide in non-insulin-dependent diabetes in the fasting state. Scand J Gastroenterol (1985) 20(3):315-320.
11. Jorde R, Burhol PG: The insulinotropic effect of gastric inhibitory polypeptide in non-insulin dependent diabetes. Ital J Gastroenterol (1987) 19:76-78.
12. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest (1993) 91(1):301-307.
13. Meier JJ, Hücking K, Holst JJ, Deacon CF, Schmiegel W, Nauck MA: Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes (2001) 50(11):2497-2504.
14. Meier JJ, Nauck MA, Schmidt WE, Gallwitz B: Gastric inhibitory polypeptide: The neglected incretin revisited. Regul Pept (2002) 107(1-3):1-13.
15. Byrne MM, Gliem K, Wank U, Arnold R, Katschinski M, Polonsky KS, Goke B: Glucagon-like peptide 1 improves the ability of the β-cell to sense and respond to glucose in subjects with impaired glucose tolerance. Diabetes (1998) 47(8):1259-1265.
16. Ritzel R, Schulte M, Nauck M, März W, Porksen N, Schmiegel W, Nauck MA: GLP-1 increases secretory burst mass of pulsatile insulin secretion in patients with impaired glucose tolerance and type 2 diabetes (abstracts). Diabetologia (1998) 41(Suppl 1):A182.
17. Gutniak MK, Ørskov C, Holst JJ, Åhren B, Efendic S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med (1992) 326(20):1316-1322.
18. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Nauck MA: Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagonlike peptide 1 in patients with type 2 diabetesW. J Clin Endocrinol Metab (2003) 88(6):2719- 2725.
19. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycaemia by exogenous glucagonlike peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia (1993) 36(8):741-744.
20. Vilsbøll T, Krarup T, Madsbad S, Holst JJ: No reactive hypoglycaemia in type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. Diabetic Med (2001) 18(2):144-149.
21. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hufner M, Schmiegel WH: Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab (2002) 87(3):1239-1246.
22. Kreymann B, Williams G, Ghatei MA, Bloom SR: Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet (1987) 2(8571):1300-1304.
23. Creutzfeldt WO, Kleine N, Willms B, Ørskov C, Holst JJ, Nauck MA: Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care (1996) 19(6):580-586.
24. Freyse EJ, Becher T, El-Hag O, Knospe S, Goke B, Fischer U: Blood glucose lowering and glucagonostatic effects of glucagon-like peptide I in insulin-deprived diabetic dogs. Diabetes (1997) 46(5):824-828.
25. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ: Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci (1993) 38(4):665-673.
26. Wettergren A, Wojdemann M, Holst JJ: Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol (Gastrointest Liver Physiol) (1998) 275(5 Pt 1):G984-G992.
27. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH: Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol (Endocrinol Metab) (1997) 273(5 Pt 1):E981-E988.
28. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP et al: A role for glucagon-like peptide-1 in the central regulation of feeding. Nature (1996) 379(6560):69-72.
29. Flint A, Raben A, Astrup A, Holst JJ: Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest (1998) 101(3):515-520.
30. Gutzwiller JP, Göke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, Winterhalder R, Conen D, Beglinger C: Glucagon-like peptide-1: A potent regulator of food intake in humans. Gut (1999) 44(1):81-86.
31. Gutzwiller J-P, Drewe J, Göke B, Schmidt H, Rohrer B, Lareida J, Beglinger C: Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol (Regulat Integrat Comparat Physiol) (1999) 276(5 Pt 2):R1541-R1544.
32. Meier JJ, Gallwitz B, Schmidt WE, Nauck MA: Glucagon-like peptide 1 as a regulator of food intake and body weight: Therapeutic perspectives. Eur J Pharmacol (2002) 440(2-3):269-279.
33. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: A parallel-group study. Lancet (2002) 359(9309):824-830.
34. Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA: Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes (2000) 49(4):611-617.
35. Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA: Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia (2002) 45(10):1410-1415.
36. Prigeon RL, Quddusi S, Paty B, D'Alessio DA: Suppression of glucose production by GLP-1 independent of islet hormones: A novel extrapancreatic effect. Am J Physiol (Endocrinol Metab) (2003) 285(4):701-707.
37. Xu G, Stoffers DA, Habener JF, Bonner-Weir S: Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes (1999) 48(12):2270-2276.
38. Zhou J, Wang X, Pineyro MA, Egan JM: Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes (1999) 48(12):2358-2366.
39. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, Perfetti R: Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology (2002) 143(11):4397- 4408.
40. Hui H, Nourparvar A, Zhao X, Perfetti R: Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology (2003) 144(4):1444- 1455.
41. Perfetti R, Zhou J, Doyle ME, Egan JM: Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology (2000) 141(12):4600-4605.
42. Buteau J, Foisy S, Rhodes CJ, Carpenter L, Biden TJ, Prentki M: Protein kinase Cζ activation mediates glucagon-like peptide-1-induced pancreatic β-cell proliferation. Diabetes (2001) 50(10):2237-2243.
43. Buteau J, Foisy S, Joly E, Prentki M: Glucagon-like peptide 1 induces pancreatic β-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes (2003) 52(1):124-132.
44. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R: Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology (2003) 144(12):5149-5158.
45. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC: β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes (2003) 52(1):102-110.
46. Ritzel RA, Butler PC: Replication increases β-cell vulnerability to human islet amyloid polypeptide-induced apoptosis. Diabetes (2003) 52(7):1701-1708.
47. Mentlein R, Gallwitz B, Schmidt WE: Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem (1993) 214(3):829-835.
48. Ritzel R, Ørskov C, Holst JJ, Nauck MA: Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Doseresponse-relationships. Diabetologia (1995) 38(6):720-725.
49. Deacon CF, Johnsen AH, Holst JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab (1995) 80(3):952-957.
50. Pauly RP, Rosche F, Wermann M, McIntosh CH, Pederson RA, Demuth HU: Investigation of glucose-dependent insulinotropic polypeptide(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach. J Biol Chem(1996) 271(38):23222-23229.
51. 2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab (2003) 88(4):1772-1779.
52. Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agersø H, Veldhuis J, Porksen N, Schmitz O: Bedtime administration of NN2211, a longacting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes (2002) 51(2):424-429.
53. Nauck MA, Wollschläger D, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Willms B: Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia (1996) 39(12):1546-1553.
54. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD: Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab (2003) 88(7):3082- 3089.
55. Malmberg K: Prospective randomised study of intensive treatment on long term survival after myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes mellitus, Insulin Glucose infusion in Acute Myocardial Infarction) Study Group. Br Med J (1997) 314(7093):1512-1515.
56. Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenström A, Wedel H: Mortality prediction in diabetic patients with myocardial infarction: Experiences from the DIGAMI study. Cardiovasc Res (1997) 34(1):248-253.
57. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in the critically ill patients. N Engl J Med (2001) 345(19):1359-1367.
58. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC: Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: A systematic overview. Stroke (2001) 32(10):2426-2432.
59. Meier JJ, Weyhe D, Michaely M, Senkal M, Schmidt WE, Nauck MA, Holst JJ, Gallwitz B: Intravenous glucagon-like peptide 1 (GLP-1) is a feasible treatment after major surgery in patients with type 2 diabetes (abstract). Diabetologia (2003) 46(Suppl 2):A286.
60. Nauck MA, Walberg J, Vethacke A, El-Ouaghlidi A, Senkal M, Holst JJ Gallwitz B, Schmidt WE, Schmiegel W: Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regul Pept (2004) 118(1-2):89-87.
61. Toft-Nielsen M-B, Madsbad S, Holst JJ: Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care (1999) 22(7):1137-1143.
62. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth HU: Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes (1998) 47(8):1253-1258.
63. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X: Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia (1999) 42(11):1324-1331.
64. Åghren B, Holst JJ, Martensson H, Balkan B: Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol (2000) 404(1-2):239-245.
65. Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ: Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol (2002) 172(2):355-362.
66. Sudre B, Broqua P, White RB, Ashworth D, Evans DM, Haigh R, Junien JL, Aubert ML: Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes (2002) 51(5):1461-1469.
67. Pospisilik JA, Stafford SG, Demuth HU, Brownsey R, Parkhouse W, Finegood DT, McIntosh CH, Pederson RA: Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and β-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes (2002) 51(4):943-950.
68. Åhren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist M, Bavenholm P, Efendic S, Eriksson JW, Dickinson S et al: Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care (2002) 25(5):869-875.
69. Mentlein R: Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept (1999) 85(1):9-24.
70. Gorrell MD, Gysbers V, McCaughan GW: CD26: A multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol (2001) 54(3):249-264.
71. Bock O, Kreiselmeyer I, Mrowietz U: Expression of dipeptidylpeptidase IV (CD26) on CD8+ T cells is significantly decreased in patients with psoriasis vulgaris and atopic dermatitis. Exp Dermatol (2001) 10(6):414-419.
72. Rose M, Hildebrandt M, Fliege H, Seibold S, Monnikes H, Klapp BF: T-cell immune parameters and depression in patients with Crohn's disease. J Clin Gastroenterol (2002) 34(1):40-48.
73. Siegel EG, Gallwitz B, Scharf G, Mentlein R, Morys-Wortmann C, Fölsch UR, Schrezenmeir J, Drescher K, Schmidt WE: Biological activity of GLP-1-analogues with N-terminal modifications. Regul Pept (1999) 79(2-3):93-102.
74. Gallwitz B, Ropeter T, Morys-Wortmann C, Mentlein R, Siegel EG, Schmidt WE: GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro. Regul Pept (2000) 86(1-3):103-111.
75. Xiao Q, Giguere J, Parisien M, Jeng W, St-Pierre SA, Brubaker PL, Wheeler MB: Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. Biochemistry (2001) 40(9):2860-2869.
76. Kapitza C, Trautmann ME, Heise T, Heinemann L, Patterson B: Daily administration of LY307161SR (GLP-1 Analog) normalizes blood glucose in type 2 diabetes. Diabetes (2002) 51(Suppl 2):A84.
77. Trautmann ME, Kapitza C, Mace KF, Patterson B, Hompesch M, Heise T: LY307161 SR, a sustained release formulation of a GLP-1 analog, is suitable for once daily administration in patients with type 2 diabetes. Diabetes (2002) 51(Suppl 1):A135.
78. Trautmann M, Chen C-F, Chappell J, Dananberg J, Patterson B, Klausmann G, Kapitza C: LY307161 SR, a long-acting GLP-1 analog, improved glycemic control in patients with type 2 diabetes. Diabetes (2003) 52(Suppl 1):A136.
79. Eli Lilly & Co: Drug development pipeline: LY-307161. Company Communication (2004) February 23.
80. Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M: The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia (2002) 45(2):195-202.
81. Elbrønd B, Jakobsen G, Larsen S, Agersø H, Jensen LB, Rolan P, Sturis J, Hatorp V, Zdravkovic M: Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care (2002) 25(8):1398-1404.
82. Larsen PJ, Tang-Christensen M, Knudsen LB: Systemic administration of the long-acting GLP-1 analogue, NN2211, induces lasting and reversible loss of body obesity. Diabetologia (2001) 43(Suppl 1):A144.
83. Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, Knudsen LB: The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice. Am J Physiol (Endocrinol Metab) (2002) 283(4):E745-E752.
84. Ribel U, Larsen MO, Rolin B, Carr RD, Wilken M, Sturis J, Westergaard L, Deacon CF, Knudsen LB: NN2211: A long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. Eur J Pharmacol (2002) 451(2):217-225.
85. Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, An B, Galecki A, Halter JB: The GLP-1 derivative NN2211 restores β-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes (2003) 52(7):1786-1791.
86. Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jette L, Benquet C, Drucker DJ: Development and characterization of a glucagon-like peptide 1-albumin conjugate: The ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes (2003) 52(3):751-759.
87. Lawrence B, Dreyfus JF, Wen S, Guivarch P-H, Drucker DJ, Castaigne J-P: CJC-1131, a long-acting GLP-1 derivative, exhibits an extended pharmacokinetic profile in healthy human volunteers. Diabetes (2003) 52(Suppl 1):A125.
88. Eng J, Kleinman WA, Singh G, Raufman JP: Isolation and characterisation of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem (1992) 267(11):7402-7405.
89. Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Göke B: Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. J Biol Chem (1993) 268(26):19650-19655.
90. Chen YE, Drucker DJ: Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem (1997) 272(7):4108-4115.
91. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD: Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care (2003) 26(8):2370-2377.
92. Greig NH, Holloway HW, De Ore KA, Jani D, Wang Y, Zhou J, Garant MJ, Egan JM: Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia (1999) 42(1):45-50.
93. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M: Glucose-lowering and insulin-sensitizing actions of exendin-4: Studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes (1999) 48(5):1026-1034.
94. Egan JM, Clocquet AR, Elahi D: The insulinotropic effect of acute exendin-4 administered to humans: Comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab (2002) 87(3):1282-1290.
95. Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RGS, Greig NH, Egan JM: Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology (2000) 141(6):1936-1941.
96. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, Bloom SR: Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol (Endocrinol Metab) (2001) 281(1):E155-E161.
97. Tourrel C, Bailbe D, Meile MJ, Kergoat M, Portha B: Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin- treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes (2001) 50(7):1562-1570.
98. ørskov C, Poulsen SS: Glucagon-like peptide 1 (7-36)-amide receptors only in islets of Langerhans. Audioradiographic survey of extracerebral tissues in rats. Diabetes (1991) 40(10):1292- 1296.
99. Buteau J, Roduit R, Susini S, Prentki M: Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in β (INS-1)-cells. Diabetologia (1999) 42(7):856-864.
100. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB: Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol (Gastrointest Liver Physiol) (1997) 273(4 Pt 1):G920-G927.
101. ørskov C, Poulsen SS, Møller M, Holst JJ: Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes (1996) 45(6):832-835.
102. Dillon JS, Tanizawa Y, Wheeler MB, Leng XH, Ligon BB, Rabin DU, Yoo-Warren H, Permutt MA, Boyd AE: Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor. Endocrinology (1993) 133(4):1907-1910.
103. Wei Y, Mojsov S: Tissue-specific expression of the human receptor for glucagon-like peptide-I: Brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett (1995) 358(3):219-224.
104. Egan JM, Montrose-Rafizadeh C, Wang Y, Bernier M, Roth J: Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulinstimulated glucose metabolism in 3T3-L1 adipocytes: One of several potential extrapancreatic sites of GLP-1 action. Endocrinology (1994) 135(5):2070-2075.
105. Villanueva-Penacarrillo ML, Alcantara AI, Clemente F, Delgado E, Valverde I: Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia (1994) 37(11):1163-1166.
106. Ørskov L, Holst JJ, Moller J, Ørskov C, Moller N, Alberti KG, Schmitz O: GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia (1996) 39(10):1227-1232.
107. Ryan AS, Egan JM, Habener JF, Elahi D: Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulinmediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab (1998) 83(7):2399-2404.
108. Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC: Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes (1996) 45(11):1524-1530.
109. Deacon CF, Hughes TE, Holst JJ: Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes (1998) 47(5):764-769.
110. Trautmann M, Payne C, Roberts E, Pascoe S: LY307161, a glucagon like peptide (GLP-1) analogue with prolonged action, does not cause hypoglycemia. Diabetologia (2000) 43(Suppl 1):146.
111. Kim J-G, Baggio LL, Drucker DJ: The GLP-1-DAC analogue CJC-1131 upregulates insulin gene expression and exerts a memory effect on glycemic control in db/db mice. Diabetes (2002) 51(Suppl 2):A340.
112. Lawrence B, Wen SY, Jette L, Thibaudeau K, Castaigne J-P: CJC1131, the novel acting GLP-1 analogue, delays gastric emptying and demonstrates safety and tolerability in preclinical testing. Diabetes (2002) 51(Suppl 2):A84.